'Twas the night before Christmas "...while visio
Post# of 72447
(Total Views: 169)
Posted On: 12/19/2017 4:30:50 PM
'Twas the night before Christmas "...while visions of sugarplums danced thru their heads" speaks of what children look forward to during this Christmas Season.
But what do IPIX shareholders have dancing thru their heads?
Q1 B-OM partnership ( at least for non - USA market) that will capture a $1B+ market with the ONLY preventative product on the market. What will be the effect on the share price? Since it will likely lead to an exchage uplisting, large reserve of cash, name recognition worldwide, validation of IPIX as a continuing entity, and an entry point for institutional investors to start buying our stock I would say at least a couple of dollars.
Now realize the OM market is about the smallest revenue target our products will be going after and we expect to be first in class (or darn close) in most of them when you take into acct efficacy, safety, lack of side effects, etc. Some of our targets are in the tens of billions per year and cancer over the moon.
When will we have a pretty good idea as to the future for all our products:
Brilacidin already shown to be highly effective in ABSSSI, UP, sigmoid UP, and OM. Future indications numerous and many not even discovered yet. Dermatology applications extremely exciting and revenue potential staggeringly large, both acne and eczema markets in the tens of billions, not to mention the smaller markets of more egregious forms of skin problems and lesions. Possible drug of choice for problems of the entire GI tract to include colitis and Chron's Disease, not to mention arthritis. Some have spoken of it as the lead product of a new class of medicine, namely synthetic defensin protein mimetics, and the possibility that it could become the drug of the decade. This is the ultimate goal, admittedly a very long shot, but still a shot nonetheless.
Prurisol Mainly a psoriasis cure and a possibility to become first in prescription by doctors due to its cost, oral delivery system, efficacy, and safety features compared to the biologics and Otezla. Trial done this week or next and top line data due Q1. Possible LARGE deal shortly after all data released unless trial data is as strong as expected and then a deal may come about after release of top line only (this is a WAG on my part but BP will realize they can't sit on their thumbs with such a powerful product being prized by many BP's).
Kevetrin The most iffy of our products but the baby of Dr Menon and the product I believe he thinks will win him the Nobel Prize. We get interim data within a matter of days to weeks and if the MOA shows what we expect, it could become the darling drug of choice for cancer combo drugs across a wide, wide span of cancers and will be on the lips of every oncologist worldwide.
Being a kid is fun, but as noted above being a IPIX shareholder makes sugarplums look pretty sad.
God bless us everyone!!!
But what do IPIX shareholders have dancing thru their heads?
Q1 B-OM partnership ( at least for non - USA market) that will capture a $1B+ market with the ONLY preventative product on the market. What will be the effect on the share price? Since it will likely lead to an exchage uplisting, large reserve of cash, name recognition worldwide, validation of IPIX as a continuing entity, and an entry point for institutional investors to start buying our stock I would say at least a couple of dollars.
Now realize the OM market is about the smallest revenue target our products will be going after and we expect to be first in class (or darn close) in most of them when you take into acct efficacy, safety, lack of side effects, etc. Some of our targets are in the tens of billions per year and cancer over the moon.
When will we have a pretty good idea as to the future for all our products:
Brilacidin already shown to be highly effective in ABSSSI, UP, sigmoid UP, and OM. Future indications numerous and many not even discovered yet. Dermatology applications extremely exciting and revenue potential staggeringly large, both acne and eczema markets in the tens of billions, not to mention the smaller markets of more egregious forms of skin problems and lesions. Possible drug of choice for problems of the entire GI tract to include colitis and Chron's Disease, not to mention arthritis. Some have spoken of it as the lead product of a new class of medicine, namely synthetic defensin protein mimetics, and the possibility that it could become the drug of the decade. This is the ultimate goal, admittedly a very long shot, but still a shot nonetheless.
Prurisol Mainly a psoriasis cure and a possibility to become first in prescription by doctors due to its cost, oral delivery system, efficacy, and safety features compared to the biologics and Otezla. Trial done this week or next and top line data due Q1. Possible LARGE deal shortly after all data released unless trial data is as strong as expected and then a deal may come about after release of top line only (this is a WAG on my part but BP will realize they can't sit on their thumbs with such a powerful product being prized by many BP's).
Kevetrin The most iffy of our products but the baby of Dr Menon and the product I believe he thinks will win him the Nobel Prize. We get interim data within a matter of days to weeks and if the MOA shows what we expect, it could become the darling drug of choice for cancer combo drugs across a wide, wide span of cancers and will be on the lips of every oncologist worldwide.
Being a kid is fun, but as noted above being a IPIX shareholder makes sugarplums look pretty sad.
God bless us everyone!!!
(5)
(0)